You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Can Gilead's big run in 2013 be replicated in 2014?
In this video, as part of The Motley Fool's "Ask a Fool" series, health-care analyst David Williamson takes a question from a Fool reader, who asks:
Gilead Sciences (GILD 0.38%) seems to be on a down trend. Is there any specific reason, or should I just hold firm?
David Williamson owns shares of AbbVie. Follow David on Twitter: @MotleyDavid.
The Motley Fool recommends Gilead Sciences. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
